SCHEMBL1403591

SCHEMBL1403591

O=C(O)c1ccc(NCc2ccccc2)cc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 2/20 0.59
GAA P10253 1/20 0.59
HPGD P15428 1/20 0.59
KDM4C Q9H3R0 1/20 0.57
NOX4 Q9NPH5 1/20 0.55
HAO1 Q9UJM8 1/20 0.54
PPARA Q07869 1/20 0.54
STING1 Q86WV6 1/20 0.54
KMT2A Q03164 1/20 0.53
FFAR1 O14842 1/20 0.53
FFAR4 Q5NUL3 1/20 0.53
MRGPRX4 Q96LA9 1/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
HCAR2 Q8TDS4 1/20 0.50
ASPH Q12797 1/20 0.50
RIOX2 Q8IUF8 1/20 0.50
KDM8 Q8N371 1/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079654 0.87 KDM4C (0.58) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL611490 0.87 KDM4C (0.76) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL29532272 0.87 KDM4C (0.76) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL26356618 0.85 KDM4E (0.55) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL1403529 0.85 APEX1 (0.50) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL1403640 0.84 RAB9A (0.54) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL11222099 0.84 KDM4C (0.52) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL1403639 0.81 CA1 (0.66) KDM4EALDH1A1GAAHPGDNOX4
SCHEMBL7985611 0.81 PTPN1 (0.52) KDM4EALDH1A1GAAHPGDKDM4C
SCHEMBL31227771 0.79 PPARA (0.80) ALDH1A1KDM4CNOX4PPARASTING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327013-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2019-04-24 EP disclosed
EP-3327013-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2018-05-30 EP disclosed
EP-3061758-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2018-01-31 EP disclosed
US-9801868-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2017-10-31 US disclosed
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2016-12-01 US disclosed
US-9447070-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2016-09-20 US disclosed
EP-3061758-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2016-08-31 EP disclosed
EP-2749559-B1 5-substituted isoindoline compounds CELGENE CORP (US) 2016-04-27 EP disclosed
EP-2291365-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2015-03-11 EP disclosed
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2015-01-01 US disclosed
US-8877780-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-11-04 US disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 EP disclosed
EP-2057143-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2013-07-24 EP disclosed
CN-102112463-A 5-substituted isoindoline compounds CELGENE CORP 2011-06-29 CN disclosed
EP-2291365-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2011-03-09 EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 WO disclosed
CN-101578277-A 5-substituted isoindoline compounds CELGENE CORP (US) 2009-11-11 CN disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 US disclosed
EP-2057143-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-05-13 EP disclosed
WO-2008027542-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 KDM4E 2637/4885ALDH1A1 403/4885GAA 1763/4885
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 KDM4E 2637/4885ALDH1A1 403/4885GAA 1763/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 KDM4E 2637/4885ALDH1A1 403/4885GAA 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.